ERBB2 and cancer: The most promising LNP formulation was loaded with the DNA vaccine pVAX-hECTM targeting the human neoantigen HER2, an oncoprotein that is overexpressed in several cancers and that represents an ideal immunogenic target for tumor vaccines [15].